THE ARISING · Markets & Strategy · Long reads
Moderna's 2026 Rally Tops 500%, Driven Mostly by One Melanoma Vaccine Trial
A Phase 3 win for a personalized mRNA cancer vaccine sent Moderna shares soaring. The stock is up more than 500 percent this year, about sixfold, though part of that gain came before the trial result. The science is real; the product is not yet approved, and the stock is pricing a lot of hope.
Moderna began 2026 as a fading pandemic stock trading near $30. By late September it was around $190. One clinical result explains most of that climb: a personalized mRNA vaccine that helped keep melanoma from coming back. The shares had already roughly doubled, to about $63 to $70, before that result.
Our research desk reported that Moderna rose another 5 percent in late September and was up roughly 500 percent for the year. It credited the company's mRNA cancer vaccine program, attributed the run's continuation despite valuation worries to Yahoo Finance, and read the move as a momentum trade first and a platform bet second.
The catalyst is confirmed. On August 19, Merck and Moderna announced that the Phase 3 trial INTerpath-001 met its main goal, according to AJMC. The vaccine, intismeran autogene, was given with the immunotherapy pembrolizumab (Keytruda) after surgery.
The trial enrolled 1,137 people with fully removed stage IIB to IV melanoma. Adding the vaccine improved recurrence-free survival and distant metastasis-free survival at a planned interim look. No new safety signals were reported. The companies had not released Phase 3 hazard ratios at the time of the announcement, and overall survival is still being measured.
Earlier, smaller data point the same way. In the Phase 2b study, five-year follow-up showed a hazard ratio of 0.51 for recurrence or death, about half the risk, per the same AJMC report. That trial was much smaller, and its wide confidence interval (0.294 to 0.887) means the estimate is less certain.
The stock math holds, and the gain is larger than our desk said. A market-data chart note records a close of $174.38 on August 19, up from $62.96 the day before, with the year's starting price at $30.86. Monthly price history shows about $29.49 at the end of 2025 and about $192.57 for September 2026, roughly 6.5 times the starting price, or a gain of about 550 percent. The one-day jump accounts for most of the year's gain, but not all of it.
We could not open the Yahoo Finance piece our desk cited, and we could not confirm the specific 5 percent daily gain. Valuation worries do appear in other outlets, and Citi downgraded the stock in late September.
This is the first late-stage success for an mRNA cancer therapy. Each dose is built from the patient's own tumor mutations, then trains the immune system to hunt cells that carry them. If the full data hold, it validates a platform that could extend to other cancers.
It also shows how markets treat medical news. The stock priced in approval, sales and a broader platform within weeks, and has kept climbing since: about $245.81 in October by one price history, and about 658 percent up for the year at $223.60 premarket on October 15 per 24/7 Wall St. Moderna rejoined the Nasdaq-100 on October 9 and raised about $2 billion in convertible notes after the jump, according to Bloomberg Law. Regulators have not yet ruled, and full results have not been presented at a medical meeting.
• If you or a family member had high-risk melanoma removed, ask your oncologist whether a vaccine trial or expanded-access program fits. • Keep up yearly skin checks if you have many moles, fair skin or a family history of melanoma. • Use sun protection year round; prevention still beats any vaccine. • Treat a soaring health stock as a story about expectations, not proof a treatment works for you.
• Phase 3 hazard ratios were not public at the announcement. The size of the benefit is unknown until full data appear, and they may be out by the time you read this. • Overall survival is open. Fewer recurrences usually help, but survival is the outcome patients care about most. • Cost and logistics. A vaccine made for each patient is expensive and slow to produce. Access will be a real question. • Our desk's "5 percent" and Yahoo citation could not be confirmed.
• Full INTerpath-001 data, scheduled for ESMO 2026 (Presidential Symposium, LBA1, Madrid, October 24), including hazard ratios. • Any regulatory filing announcement from Merck and Moderna. • Overall survival updates, the result that should matter most to patients. Not financial advice. Facts and context only.
Do Driverless Mine Trucks Win by Being Steady, Not Fast? AI Agents Breached Hugging Face: What It Means for Medical AI Appeals Court Upholds Pentagon's Anthropic Label; Dispute Is About AI Safeguards